Myocardial infarction in major noncardiac surgery: Epidemiology, pathophysiology and prevention by LUCREZIOTTI, STEFANO et al.
1826-1868/082-12$15.00/0
Throughout recent years the approach to candidates
for noncardiac surgery has significantly evolved.
Due to the wide diffusion of less invasive surgical ap-
proaches and the improvement in anesthetic tech-
niques and perioperative monitoring, indications to ma-
jor noncardiac surgery have been extended to individu-
als prone to cardiac complications. 
As a result, noncardiac operations may treat disease
and improve quality of life even in such categories of
patients, but at the expense of cardiac mortality and
morbidity, prolonged hospitalizations, and consequent
costs.
About half of the 100 million/year adults undergoing
noncardiac surgery worldwide are old and it is likely that
the number of old patients undergoing noncardiac oper-
ations in the USA will double within the coming years
(from 6 million to 12 million/year) (1, 2).
EPIDEMIOLOGY: AS A CORRECT
DIAGNOSIS MAY INFLUENCE THE PRECISE ESTIMATION
OF THE INCIDENCE OF CARDIAC EVENTS
It has been estimated that 500,000 to 900,000 pa-
tients suffer from fatal and nonfatal perioperative car-
diovascular complications annually (2).
Excluding cardiac arrest which portends a risk of in-
hospital mortality of 65% (3), the most threatening com-
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ABSTRACT: The number of subjects undergoing major noncardiac surgery who are at risk for
perioperative myocardial infarction (MI) is growing worldwide.
It has been estimated that 500,000 to 900,000 patients suffer major perioperative cardiovascu-
lar complications every year, with consequent heavy, long-term prognostic implications and
costs.
It is well known that perioperative MIs don’t share the same pathophysiology as nonsurgical MIs
but the relative role of the different, potential triggers has not been completely clarified.
Many aspects of the perioperative management, including risk-stratification and prophylactic or
postoperative interventions have also not been completely defined.
Throughout recent years many resources have been invested to clarify these aspects and ex-
perts have developed indices and algorithm-based strategies to better assess the cardiac risk
and to guide the perioperative management.
The scope of the present review is to discuss the main aspects of perioperative MI in noncardiac
surgery, with particular regard to epidemiology, pathophysiology, preoperative risk stratification,
prophylaxis and therapy. (Heart International 2006; 2: 82-93)
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plications are represented by the wide spectrum of
acute coronary syndromes. Perioperative myocardial is-
chemia is significantly associated with a high risk of
subsequent cardiovascular events (OR: 2.8; 95%CI:
1.6-4.9), while perioperative myocardial infarction (MI)
is associated with an in-hospital mortality of 15%-25%
(4-8).
Unfortunately, a large proportion of ischemic episodes
go undetected during surgery and in the postoperative
period.
Thus, myocardial ischemia occurs undiagnosed and
physicians do not administer therapy and do not pro-
gram secondary prevention in patients who have suf-
fered from perioperative unstable angina or MI. The lack
of an adequate management further raises the risk of
subsequent cardiac events.
The correct estimation of the perioperative incidence
of myocardial ischemic events, particularly MI, is 
hampered by the low accuracy of the traditional diag-
nostic criteria (i.e. typical symptoms, electrocardio-
graphic (ECG) modifications, elevations in plasma lev-
els of markers of myocardial injury) (9) during and after
surgery.
It has been shown that:
￿ Patients rarely experience angina pectoris and other
ischemic symptoms immediately after surgery, be-
cause of the persistence of somatic pain secondary to
surgical trauma and the effect of anesthetic and anal-
gesic drugs (4, 5, 7).
￿ ST-segment changes, either on continuous monitoring
or on 12-lead ECG, have been shown to have a low
sensitivity and specificity (≈70%). Moreover, signifi-
cant ST-segment changes may resolve before the time
the 12-lead ECG is repeated (1, 10). 
￿ New Q-waves appear infrequently on 12-lead ECG be-
cause most perioperative MIs are non-transmural.
￿ Moreover, some ECG analyses are influenced by
Pace-Maker rhythm, left bundle branch block or
chronic ST-segment changes.
￿ The perioperative measurements of the creatine-ki-
nase (CK)’s cardiac-specific subunit (CK-MB) are
prone to false-positive and false-negative results (11).
Thus, physicians should consider a more specific and
more sensitive cardiac marker in the diagnosis of MI
after surgery. 
￿ A perioperative rise in plasma level of cardiac Troponin
(cTn), has been demonstrated to be more effective
than traditional diagnostic methods, such as ECG,
echocardiography, and CK-MB (12). 
￿ However, it should be specified that myocardial dam-
age in the absence of either ischemic symptoms or di-
agnostic ECG, may be secondary to mechanisms oth-
er than ischemia (9).
￿ The incidence of perioperative MI, when diagnosed by
elevation in cTns (12,14-27), is higher than that report-
ed in the pre-cTns studies (<1% in the general popula-
tion and 15% in high-risk patients undergoing vascu-
lar surgery) (13). Moreover, the elevation in cTns has
been demonstrated to predict short- and long-term
prognosis in most studies (Tab. I) (12,14-27).
￿ In the study by Higham et al, the correlation between
cTns and future cardiac events was not statistically
significant when authors considered cTnT, while cTnI
maintained its one-year predictive power (23).
￿ Also in the study by Filipovic et al, elevations in cTn
didn’t correlate with one-year cardiac mortality, but
the analysis excluded those patients who died in the
first 30 postoperative days (22). When the whole pop-
ulation was included in the analysis, the correlation re-
sulted significant (p<0.0001) (17).
￿ Inter-study discrepancies may depend on the differ-
ence in cTns cut-off, enrolled population, type of
surgery length of follow-up, and in the definition of
cardiac end-points.
PATHOPHYSIOLOGY OF PERIOPERATIVE MI
Atherosclerosis is the common substrate of almost
every MI, but the trigger is the formation of a luminal
thrombus on a ruptured/fissured atherosclerotic plaque.
Acute coronary syndromes presenting with ST-seg-
ment elevation are determined by an occlusive luminal
thrombus, while non ST-segment elevation acute coro-
nary syndromes present a non-occlusive thrombus.
Vessel spasm, microvascular dysfunction, a rise in
myocardial oxygen consumption may also play a role in
acute coronary syndromes (28-30).
The pathophysiology of perioperative MI is more
complex because during and after surgery, unlike the
nonsurgical setting, many alterations in homeostasis
may favor or initiate the ischemic cascade itself. This
aspect may have important management implications.
In the perioperative period, metabolic factors sec-Myocardial infarction and noncardiac surgery
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ondary to surgical trauma, anesthesia withdrawal, pain,
shift in volume, hypothermia, and fasting may activate
coagulation, platelet activation, inflammation, oxygen
consumption, cathecolamines and cortisol secretion
(31-34).
Conflicting evidence emerges from angiographic and
autoptic studies which have been conducted to better
clarify the pathophysiology of perioperative MI (35-37):
the non-homogeneous characteristics of the popula-
tions enrolled and the lack of standardization of cardiac
events may in part explain those differences.
The relative role of fixed coronary artery stenoses
and plaque thrombosis in the pathophysiology of peri-
operative MIs is not clear.
TABLE I - PERIOPERATIVE ELEVATIONS IN CARDIAC TROPONIN I OR T: INCIDENCE AND PROGNOSTIC POWER
Study Type of surgery Pts n° >cTn (%) Association of >cTn with outcome Outcome  F-U
Adams (12) Vascular; spinal 108 8 NR NR NR
Jules-Elysee (27) Orthopedic 85 6 NR NR NR
Rapp (24) Vascular 20 15 NR NR NR
Higham (23) Vascular; orthopedic 157 10 OR: 4.2 (95%CI: 1.2-14.9) with cTn I
OR: 2.4 (95%CI: 0.7-8.6) with cTn T Cardiac death;  1 year
MI; unstable 
angina; 
arrhythmias; 
heart failure
Lee (14) Vascular; orthopedic;  1175 17 RR: 9.1 IM; acute In-hospital
thoracic; abdominal;  pulmonary period
other operations edema; VF;  
cardiac arrest; 
heart block
Oscarsson (16) General; orthopedic;  564 9.7 HR: 14.9 (95%CI: 3.7-60.3) Death 1 year
vascular; gynecologic; 
urologic
Filipovic (17) Vascular; abdominal;  173 16 OR: 9.8 (95%CI: 3-32) Death 1 year
orthopedic; thoracic; 
other operations
Kim (18) Vascular 229 12 OR: 5.9 (95%CI: 1.6-22.4) Death 6 months
Landesberg (20) Vascular 447 24 OR: 2.2 (95%CI: 1.4-3.4) Death 32 months
Le Manach (21) Vascular 1136 14 OR: 8.1 (95%CI: 2.9-22.8)   Death In-hospital
with cTnI>1.5 ng/mL period
OR: 3.9 (95%CI: 1.8-8.4) 
with cTnI<1.5 ng/mL
Bursi (26) Vascular 391 22 HR: 5.5 (95%CI: 3.2-9.4) Death; MI 30 days
HR: 4.7 (95%CI: 2.9-7.7) 18 months
Vikenes (25) Thoracic 24 0 NR NR NR
Studies which excluded patients with early postoperative events 
Lopez-Jimenez (15)Vascular; orthopedic;  772 12 RR: 5.4 (95%CI: 2.2-13) Death; MI; angina 6 months
thoracic; abdominal;  pectoris requiring
other operations hospital admission
Kertai (19) Vascular 393 14 HR: 1.9 (95%CI: 1.1-3.1) Death 4.3 years
Filipovic (22) Vascular; abdominal;  167 NR Association statistically
orthopedic; thoracic;  not significant if patients who
other operations have died in the first 30 
postoperative days were 
excluded from the reference
population of the original study (17)  Death 2 years
Bursi (26) Vascular 373 NR HR: 5.5 (95%CI: 3.2-9.4) Death; MI 18 months
Abbreviations: >cTn: elevated cardiac troponin; F-U: follow-up; MI: myocardial infarction; NR: not reported; OR: odds ratio; Pts: patients;
RR: relative risk; HR: hazard ratio; VF: ventricular fibrillationLucreziotti et al
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It is likely that both the rapid increase in oxygen de-
mand in the presence of severe coronary stenoses and
the sudden decrease in oxygen delivery secondary to
acute coronary thrombosis may determine periopera-
tive myocardial ischemia (Tab. II).
HOW TO IDENTIFY HIGH-RISK PATIENTS
Given the clinical relevance of cardiac complications
in the setting of noncardiac surgery, different approach-
es for preoperative risk stratification have been pro-
posed which can be divided into clinical indices and
consensus-derived guidelines.
Clinical indices
Clinical indices are derived from statistical analysis of
a data-base of thousands of patients and assign a spe-
cific score according to the weight given to each car-
diac risk factor (8, 38-42). The best validated among
those indices is the “Revised Cardiac Risk Index” by
Lee et al (Tab. III) (38).
The advantages of risk indices are the simplicity and
the precision in risk stratification, although the main lim-
it is the lack of indications for perioperative manage-
ment, particularly supplemental preoperative testing
and prophylactic therapy.
Guidelines
The American College of Cardiology (ACC)/American
Heart Association (AHA) and American College of
Physicians (ACP) guidelines were developed in order to
guide physicians in perioperative management. They
suggest consensus-derived algorithms which allow pre-
operative cardiac risk assessment, patient’s information
and clinical decision making about perioperative diag-
nostic testing, monitoring, and therapy (1, 43, 44).
ACP guidelines are based on Detsky’s “Modified Car-
diac Risk Index” (42), while ACC/AHA guidelines derive
from the interpretation of data from various studies by a
specific Task Force.
The overriding theme of the ACC/AHA guidelines is
TABLE II - FACTORS WHICH MAY DETERMINE PERIOPERATIVE MYOCARDIAL ISCHEMIA AND MYOCARDIAL INFARCTION
Reduction of myocardial oxygen supply Increase of myocardial oxygen’s requirement
Ipoxemia Increased myocardial wall stress
changes in pulmonary function hypervolemia
weaning from the ventilator              rise in blood pressure
rise in end-diastolic left-ventricular pressure
Reduced blood pressure Arrhythmias
left ventricular dysfunction elevation in plasma cathecolamines
hypovolemia withdrawal of β-blockers
systemic vasodilatation hypotension
postoperative pain
Coronary vasospasm Changes in body temperature
Endoluminal thrombosis
enhanced platelet aggregation
hypercoagulability
impaired fibrinolysis
TABLE III - ESTIMATION OF PERIOPERATIVE CARDIAC RISK AC-
CORDING TO THE “REVISED CARDIAC RISK INDEX”
(38)
Risk factors n° Major cardiac complications *
00 . 4  %
11 . 1  %
24 . 6  %
≥ 39 . 7  %
Risk factors: high-risk surgery (abdominal aortic aneurysm, tho-
racic, abdominal); ischemic heart disease; heart failure; cere-
brovascular disease; insulin-treated diabetes; creatinine > 177
µmol/L).
* myocardial infarction, pulmonary edema, primary cardiac arrest,
complete heart blockMyocardial infarction and noncardiac surgery
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that intervention is rarely required to lower the perioper-
ative cardiac risk unless such intervention is indicated
irrespective of the surgical context (1). 
The nature of the surgical disease must be also con-
sidered. In case of urgent surgery, preoperative evalua-
tion should be rapid, so as not to delay the operation,
while a more precise evaluation can be conducted soon
after surgery.
Sometimes an extensive workup may add significant
delays to surgery without adding any further advantage
and with possible, heavy consequences in certain
groups of patients, for example those affected by can-
cer and waiting for life-saving operations. 
Extensive and redundant preoperative cardiac evalu-
ation can also result in morbidity, higher costs and re-
fusal to undergo surgery (45).
The stepwise approach is based on the definition of
the patient’s clinical status and the surgery’s cardiac
risk (Tabs. IV and V). Supplemental testing should be
performed only if it is likely to influence the patient’s
treatment and outcome (1).
Unlike ACP guidelines, which have never been vali-
dated prospectively, some studies have demonstrated
that application of the ACC/AHA guidelines in daily clin-
ical practice may help physicians in risk stratification,
may reduce hospital length of stay and costs, and may
improve prognosis (26, 46-50).
However, Bursi et al have recently demonstrated that
despite a rigorous implementation of ACC/AHA algo-
rithms, patients undergoing major vascular surgery still
remain at high risk of perioperative cardiac events (26).
In particular, among clinically stable patients who
had undergone coronary revascularization in the last 5
years, about 50% had a postoperative elevation in cTnI
and the event-free survival at 30 days was as high as
72% (26).
According to the recommendations of the ACC/AHA
guidelines, those patients were scheduled for surgery
without any supplemental tests, but this strategy may
have underestimated the real cardiovascular risk (1, 26,
51).
Some authors suggest that the stepwise approach of
the ACC/AHA guidelines, based on a detailed clinical
evaluation with selective use of supplemental testing
may be of limited use in some circumstances, for a vari-
ety of reasons (51).
First of all, ACC/AHA guidelines are founded on ob-
servational data obtained several years ago, when peri-
operative care was different and cTns analysis was not
available. As a consequence, the real incidence of peri-
operative MIs and the efficacy of preventive strategy
may have been underestimated. 
Moreover, the current ACC/AHA guidelines state that
in the presence of favorable stress test within the last
two years and stable symptoms, patients can undergo
surgery: this time span is probably too long. 
A procedure of coronary revascularization in the pre-
vious 5 years doesn’t warrant a favorable outcome. This
may be due to an incomplete/failed revascularization or
a progression of atherosclerotic disease in grafts or in
native vessels.
Silent ischemia and limited functional capacity may
mask high-risk features if the clinical evaluation is limit-
ed to history and physical examination. Therefore, non-
invasive screening may unmask high-risk situations in
some subgroups of patients and in some types of
surgery, independent of clinical history.
Noninvasive testing for myocardial ischemia
In a large number of surgical patients, noninvasive
testing plays an important role in defining the risk pro-
file.
In general, both exercise and pharmacological stress
testing have a high negative predictive power (90-
100%) and a non-uniform but generally low positive
predictive power (6-67%) (2).
Results from a meta-analysis that compared the
prognostic accuracy of 6 noninvasive tests suggest a
superiority of echo-dobutamine in predicting postoper-
ative cardiac events (cardiac death and nonfatal MI)
(52).
These data call for cautious interpretation because of
the limitations which emerge from many studies: weak
methods, low event-rate, heterogeneity across the re-
sults for individual test, dichotomized (positive or nega-
tive) compared to semiquantitative (extent of reversibil-
ity of myocardial defect) results, the nearly exclusive
application to vascular surgery patients which pre-
cludes broad generalizations to other surgical settings.
Besides the ischemic threshold, noninvasive tests
may investigate different parameters: an ergometric test
can determine the functional capacity, while echo-
dobutamine may assess hemodynamic parameters andLucreziotti et al
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TABLE IV - CLINICAL PREDICTORS OF INCREASED PERIOPER-
ATIVE CARDIOVASCULAR RISK (MYOCARDIAL IN-
FARCTION, HEART FAILURE, DEATH) (1)
Major
Acute coronary syndromes
￿ acute (< 7 days) or recent (7-30 gg) myocardial infarction with 
evidence of important ischemic risk by clinical symptoms or non-
invasive studies
￿ unstable or severe angina (Canadian class III/IV)
Decompensated heart failure
Significant arrhythmias
￿ high-grade atrioventricular block
￿ symptomatic ventricular arrhythmias in the presence of underly-
ing heart disease
￿ supraventricular arrhythmias with uncontrolled heart rate
Severe valvular disease
Intermediate
Mild angina (Canadian class I/II)
Previous myocardial infarction 
Compensated or previous heart failure
Diabetes mellitus (particularly insulin-dependent)
Renal insufficiency
Minor
Advanced age
Abnormal electrocardiogram (left bundle-branch block, left ven-
tricular hypertrophy, ST-T abnormalities)
Rhythm other than sinus
Reduced functional capacity
History of stroke
Uncontrolled hypertension
valvular function (1). Moreover, pharmacological testing
may be the sole option in patients with severe exercise
restrictions.
Moreover, in the absence of definitive data about the
efficacy of the different noninvasive testing, the consul-
tant should consider that the availability and the local
expertise in diagnosing coronary artery disease is more
important than the particular type of test (1).
Coronary angiography
Coronary angiography should be prescribed on the
basis of the results of noninvasive testing, while for cer-
tain categories of patients with baseline high cardiac
risk, diagnostic cardiac catheterization may be per-
formed without any previous noninvasive testing.
Recommendations for preoperative coronary angio-
graphy don’t differ from those for the nonsurgical set-
ting published by ACC/AHA (1, 53).
PREVENTION OF PERIOPERATIVE MI
Different prophylactic strategies have been tested in
order to reduce the incidence of ischemic events after
noncardiac surgery.
The cornerstones of preventive strategy are adrener-
gic modulation, atherosclerotic plaque stabilization,
and coronary artery revascularization.  
Given the complex and multifactorial pathophysiolo-
gy of perioperative MI, a relative risk reduction of more
than 35% by a single intervention is unlikely (1).
β-blockers
β-blockers enhance coronary flow, reduce myocar-
dial oxygen consumption by modulation of systemic
blood pressure, heart rate and contractility, and have
anti-arrhythmic effects. 
Although earlier studies have documented a benefi-
cial effect in patients treated with β-blockers in the pe-
rioperative period (54,55), results from recent meta-
analysis are controversial (56-58).
Such a discrepancy may probably depend on various
reasons: the inadequate statistical power and the lack
of randomization in several studies; the lack of prede-
fined target heart rate (usually, about 60 beats/min); the
paucity of data about patients at low to intermediate
cardiac risk; the lack of comparison studies between
different molecules and different routes of administra-
tion (intravenous vs oral agents).
A recent, retrospective, and very large observational
study compared the in-hospital outcome of patients re-
ceiving β-blocker therapy and those not treated with 
β-blockers (59). All patients underwent major noncar-
diac surgery and were matched according to the Re-
vised Cardiac Risk Index (38).
Surprisingly, perioperative β-blockade wasn’t asso-
ciated with an overall reduced mortality, although a
step gradient in treatment effect was observed in rela-
tion to the Revised Cardiac Risk Index score (59). β-
blocker use was associated with increased mortality
among low-risk patients, was neutral among interme-
diate-risk patients and had a beneficial effect in high-
risk patients (59).
According to the results of the few studies and theMyocardial infarction and noncardiac surgery
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TABLE V - CARDIAC RISK STRATIFICATION (COMBINED INCI-
DENCE OF CARDIAC DEATH OR NONFATAL MY-
OCARDIAL INFARCTION) FOR NONCARDIAC OPERA-
TIONS (1)
High (cardiac risk > 5%)
Emergent major operations, particularly in the elderly
Aortic and other major vascular surgery
Peripheral vascular surgery
Anticipated prolonged surgical procedures associated with large
fluid shifts and/or blood loss
Intermediate (cardiac risk < 5%)
Carotid endarterectomy
Head and neck surgery
Intraperitoneal and intrathoracic surgery
Orthopedic surgery
Prostate surgery
Low (cardiac risk < 1%)
Endoscopic and superficial procedures
Cataract surgery
Breast surgery
opinions of some authors, the use of β-blockers should
be at present limited to high-risk patients undergoing
major noncardiac surgery.
No data are available for short-stay procedures and
for minor operations.
Until the results from two ongoing randomized trials
(POISE, DECREASE IV) on the efficacy of β-blockers are
available (60,61), we suggest that physicians in charge
and consultants refer to the recently updated ACC/AHA
guidelines about perioperative β-blocker therapy (62).
α2-adrenergic agonists
α2-adrenergic agonists may reduce perioperative
cardiac events because they suppress the release of
cathecolamines.
A meta-analysis, which included 12 randomized con-
trolled trials, demonstrated a beneficial effect of α2-
adrenergic agonists in reducing mortality (RR: 0.47;
95%CI: 0.25-0.90) and myocardial infarction (RR: 0.66;
95%CI: 0.46-0.94) in patients undergoing vascular
surgery (63).
This trend was confirmed by another meta-analysis
(57) and by one subsequent randomized study which
compared clonidine with placebo in 190 patients under-
going non-cardiac surgery, with or at risk for atheroscle-
rotic disease (64). In the latter study, clonidine was sig-
nificantly associated with a reduced incidence of is-
chemic events (14% vs 31%; p = 0.01) and reduced
two-year mortality (15% vs 29%; RR: 0.43; 95% CI
0.21-0.89; p = 0.035) (64).
Although the results of randomized trials and meta-
analysis on α2-adrenergic agonists are encouraging,
they should be confirmed by large, randomized and well
powered trials.
Other anti-ischemic agents
At the moment, no definitive data support the admin-
istration of calcium-channel blockers or nitrates (57), al-
though a meta-analysis has demonstrated a benefit of
calcium-channel blockers, particularly diltiazem, in re-
ducing the risk of supraventricul arrhythmias, ischemia
or the combined end-points of death, myocardial infarc-
tion, supraventricul arrhythmias, heart failure (65).
Statins
Statin therapy may reduce perioperative cardiac
events through stabilization of coronary atherosclerotic
plaques and anti-thrombotic and anti-inflammatory ef-
fects. Their efficacy has been demonstrated in several
primary and secondary prevention studies conducted in
nonoperative setting.
Data about the efficacy of perioperative statin thera-
py derive from some observational studies (66-68) and
one small randomized trial (69): they showed a signifi-
cant reduction of cardiac mortality and morbidity in the
statin-treated group. 
However, in the absence of evidence of a broad ben-
efit of perioperative statins, they should be given only in
those patients already assuming them as home-therapy
or as new prescription in patients who meet the classi-
cal indications for the nonsurgical setting (70, 71).
Coronary revascularization
Flow-limiting coronary stenoses play an important
role in the pathogenesis of perioperative MI.
Therefore, surgical or percutaneous coronary revas-
cularization may help in preventing ischemic complica-
tions. However, perioperative MIs frequently develop at
the site of non-severe stenoses.
The available evidence on the overall benefit of coro-Lucreziotti et al
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nary revascularization (particularly coronary bypass
surgery) derive from few retrospective studies and from
one randomized clinical trial which compared coronary
revascularization with medical therapy in stable pa-
tients with a coronary anatomy suitable for revascular-
ization, undergoing major vascular surgery (72-74).
Taken together, these results suggest that prophylac-
tic coronary revascularization is of little or no benefit be-
fore noncardiac surgery.
It must also be considered that specific data relative
to patients with very high-risk conditions (unstable
angina, severely depressed left ventricular function,
aortic stenosis...) are lacking because those categories
of patients have been excluded from any analysis or
randomization.
Moreover, when planning preoperative coronary
revascularization, the relative benefit should be
weighed against the inevitable risk and the delay related
to the procedure itself (either surgical or percutaneous)
(75, 76). 
The time-delay attributable to coronary revascu-
larization may be unacceptable in certain subgroups
of patients, such as those waiting for urgent surgery
(1, 70).
Noncardiac surgery may be performed as soon as
two weeks after balloon angioplasty, about one month
after coronary artery bypass surgery, and at least six
weeks after positioning of a bare metal stent (70, 77).
Preoperative implantation of a drug-eluting stent is
not indicated because the need for long-term, double
anti-platelet therapy contrasts with the surgery-specific
hemorrhagic risk.
In conclusion, the indication for surgical or percuta-
neous coronary revascularization of the ACC/AHA prac-
tice guidelines on perioperative cardiovascular evalua-
tion for noncardiac surgery are essentially identical to
those for the nonoperative setting (78, 79). As a conse-
quence, the decision to revascularize just to lower the
cardiac risk of noncardiac surgery is appropriate only in
a small subset of high-risk patients (1). 
POSTOPERATIVE MONITORING AND MANAGEMENT
Given the silent and subtle nature of perioperative
myocardial ischemia, postoperative monitoring is need-
ed in order to promptly identify acute ischemic events.
Unresolved issues in monitoring strategy are which
diagnostic test to perform, for how long, and in which
patients.
ACC/AHA recommendations (1) for postoperative
monitoring include the execution of 12-lead ECGs soon
after surgery and on postoperative days 1 and 2 in pa-
tients with intermediate/major cardiac risk predictors
who have undergone intermediate to high-risk opera-
tions.
On postoperative days 1 and 4 (or at hospital dis-
charge, whichever comes first) plasma levels of cTns
should be measured (1).
Continuous ST-segment monitoring in patients af-
fected by ischemic heart disease and/or undergoing
high-risk surgery may enhance sensitivity to detect pe-
rioperative myocardial ischemia (1). However, in certain
subgroups of patients at low cardiac risk, the specifici-
ty of ST-segment changes is questionable.
No randomized clinical trial has specifically evaluat-
ed the optimal medical strategy in patients with periop-
erative MI. Therefore, it seems reasonable to correct
eventual precipitating factors (for example, hypoxia)
and to administer those therapies which have been
demonstrated to be effective in nonoperative MI (ACE-
inhibitors, statins, β-blockers).
Given the high bleeding risk at the surgical site, great
caution should be used when considering aggressive
anticoagulant and antiplatelet therapy. In the absence
of definitive data from randomized clinical trials, the risk
of bleeding must be weighed against the risk of subop-
timal therapy.
Thrombolytic therapy has been demonstrated to re-
duce mortality in ST-segment elevation MI unrelated to
surgery, but recent noncardiac surgery is a strong con-
traindication to thrombolytic therapy.
When angiography and revascularization may be
rapidly performed, reperfusion therapy with primary
coronary angioplasty may be the first choice in ST-seg-
ment elevation MI (1).
Early coronary angiography with eventual coronary
revascularization is also a valid option in patients with
non ST-elevation acute coronary syndromes with high-
risk features and who are able to take antiplatelet and
anticoagulant therapy (1).
Long-term management and secondary prevention
should include evaluation for left ventricular function,
residual ischemia and electrical instability, strict controlMyocardial infarction and noncardiac surgery
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CONCLUSIONS
Acute MI complicates a relevant number of noncar-
diac surgical procedures and is associated with an un-
favorable short-and long-term prognosis.
Implementation of risk indices and algorithm-based
guidelines may result in improved outcomes and opti-
mization of resources. 
There is also evidence that perioperative medical
therapies may prevent cardiac events in selected pa-
tients, while no data support the protective role of pre-
operative coronary revascularization in clinically stable
patients.
However, given the lack of well-powered randomized
clinical trials, many aspects are still not defined. 
Therefore, future research is needed to investigate
the complex pathophysiology of perioperative myocar-
dial ischemia and to determine:
￿ the correct strategy for preoperative risk-stratification
and the use of noninvasive testing to identify patients
prone to cardiac complications;  
￿ the role of prophylactic medical therapy and coronary
revascularization in relation to the characteristics of
patient and surgery;
￿ the best monitoring strategy to promptly detect MIs
and to administer an adequate therapy;
￿ the role of the different classes of drugs, whose bene-
fit has been demonstrated in nonoperative MIs, in the
early postoperative period;
￿ the optimal approach to long-term postoperative
management and secondary prevention.
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